Trials / Terminated
TerminatedNCT04752371
A Study to Evaluate Camoteskimab in Participants With Still's Disease
A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Camoteskimab in Subjects With Adult Onset Still's Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Apollo Therapeutics Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camoteskimab (CERC-007, AVTX-007, AEVI-007) | Intravenous (IV) Infusion |
Timeline
- Start date
- 2021-03-25
- Primary completion
- 2022-05-24
- Completion
- 2022-05-24
- First posted
- 2021-02-12
- Last updated
- 2023-08-23
Locations
11 sites across 4 countries: United States, Belgium, Poland, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04752371. Inclusion in this directory is not an endorsement.